Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06823479 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Towards Cure Via Only Ultra-short ICB in CSCC

Study acronym: MATISSE 2
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Feb 2025 to May 14, 2025 · Site details revised at 5 of 5 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of Feb 2025 to May 14, 2025
    • Site details revised at 5 of 5 sites
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to determine whether cutaneous squamous cell carcinoma patients can be cured using only immunotherapy, without surgery or radiotherapy.
Trial Details
NCT Number NCT06823479
Lead Sponsor The Netherlands Cancer Institute
Collaborators: UMC Utrecht, Erasmus Medical Center, Maastricht University Medical Center, Amsterdam UMC, location VUmc
Conditions Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Cutaneous Squamous Cell Carcinoma
Enrollment 41 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov